TCM
SUPN icon

TD Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

TD Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103 Sell
2
-2
-50% -$102 ﹤0.01% 841
2025
Q4 		$199 Buy
+4
New +$194 ﹤0.01% 795
2021
Q1 		– Sell
-1,492
Closed -$38K – 338
2020
Q4 		$38K Buy
+1,492
New +$32.1K 0.01% 145

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Capital Management's SUPN Position: Q1 2026 in Review

TD Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 50% in Q1 2026, selling an estimated $102 and leaving 2 shares worth $103. The position accounts for ﹤0.01% of the portfolio, ranked #841.

TD Capital Management first reported a position in SUPN in Q4 2020 and has held it in 3 quarters since. The position peaked at $38K in Q4 2020. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • TD Capital Management held 2 shares of Supernus Pharmaceuticals worth $103 as of Q1 2026.
  • TD Capital Management sold 2 Supernus Pharmaceuticals shares in Q1 2026, an estimated $102.
  • Supernus Pharmaceuticals made up ﹤0.01% of TD Capital Management's portfolio in Q1 2026, its #841 holding.
  • TD Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • TD Capital Management's Supernus Pharmaceuticals position peaked at $38K in Q4 2020.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.